retatrutide developer eli lilly announces more next-gen obesity drug data, plans Q1 2027 FDA application Lilly's new diabetes drug doubled

[3] [4] Based on Phase 2 clinical trial data published in the New England Journal of Medicine in 2023 covering both obesity and type 2 diabetes populations retatrutide was administered as a once-weekly subcutaneous injection within those trial protocols

Because neither compound is available as a commercial pharmaceutical product outside China, pricing follows research peptide market dynamics rather than pharmaceutical pricing models

While these treatments work in different ways, they may be complementary when used thoughtfully: Importantly, this is not about more medication. It is about coordinated, individualized care that addresses both body and mind

A 12-week treatment with the long-acting glucagon-like peptide 1 receptor agonist liraglutide leads to significant weight loss in a subset of obese women with newly diagnosed polycystic ovary syndrome